Management of hepatocellular carcinoma in patients who are 70 years or older

Linda L Wong; Lung Yi Lee; Kameko Karasaki; Makoto Ogihara; Chuong Tran

doi:10.1016/j.sopen.2022.07.003

Management of hepatocellular carcinoma in patients who are 70 years or older

Surg Open Sci. 2022 Jul 22:10:53-58. doi: 10.1016/j.sopen.2022.07.003. eCollection 2022 Oct.

Authors

Linda L Wong¹, Lung Yi Lee¹, Kameko Karasaki¹, Makoto Ogihara¹, Chuong Tran²

Affiliations

¹ Department of Surgery, University of Hawaii, John A. Burns School of Medicine, 1356 Lusitana St, 6th Floor, Honolulu, HI 96813.
² Department of Medicine, University of Hawaii, John A. Burns School of Medicine, 1356 Lusitana St, 7th Floor, Honolulu, HI 96813.

Abstract

Background: Although liver transplantation has been done successfully in elderly patients with hepatocellular carcinoma, these are likely well-selected patients. This study uses a large database of patients with hepatocellular carcinoma to explore treatment and potential candidacy for liver transplantation in the elderly.

Methods: Retrospective review of 1,533 hepatocellular carcinoma cases identified 2 groups: 475 patients 70 years or older (70 +) and 1,058 patients < 70 years. Demographics, risk factors, tumor characteristics, treatments, and survival were compared. Three- and 5-year survival rates were determined, and logistic regression was used to identify factors predictive of 3-year survival.

Results: Patients 70 + were more likely to have metabolic factors and less likely to have viral hepatitis, cirrhosis, hepatocellular carcinoma found with surveillance (21.7% vs 28.4%, P = .005), and hepatocellular carcinoma within Milan criteria (37.3% vs 43.8%, P = .019). Model for End-stage Liver Disease score was similar, but patients 70 + had higher mean creatinine and lower mean bilirubin. Patients 70 + were equally likely to undergo liver resection but less likely to undergo liver transplantation (0.4% vs 10.2%, P < .001). Three- and 5-year survival rates were significantly worse in 70 +, and predictors of 3-year survival included hepatocellular carcinoma found with surveillance, meeting Milan criteria, and normal alpha fetoprotein.

Discussion: Elderly patients with hepatocellular carcinoma were less likely to undergo liver transplantation potentially due to metabolic factors and advanced disease. Although there is no age cutoff for liver transplantation, elderly patients should be given realistic expectations of liver transplantation candidacy. Continued surveillance for hepatocellular carcinoma in elderly patients may allow for earlier diagnosis and improved liver transplantation candidacy.

Key message: Hepatocellular carcinoma in patients who are 70 years or older can be managed with liver transplantation in select cases, but more patients will be managed with liver resection and nonoperative therapies.